Article
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade.
Frontiers in immunology - 1 Jan 2020
Jiang Youhai, Zhao Xiaofang, Fu Jing, Wang Hongyang
Abstract excerpt
Immune checkpoint inhibitors target the inhibitory receptors on T cells to reinstate their antitumor ability and have shown significant efficacy in treating various cancers. However, because of tumor heterogeneity and many other uncover reasons, the objective response rate for programmed death 1 and programmed death-ligand 1 (PD-1/PD-L1) blockade is only 20 to 30%; its response rate in solid tumors is relatively...
Topics
- B7-H1 Antigen
- Combined Modality Therapy
- Gastrointestinal Microbiome
- Humans
- Immune Checkpoint Inhibitors
- Mutation
- Neoplasms
- Obesity
- Programmed Cell Death 1 Receptor
- Tumor Microenvironment